ASH 2023 | Asciminib plus dasatinib for the treatment of Ph+ B-ALL: insights from a Phase I trial
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase I dose-escalation trial (NCT03595917) combining the TKIs asciminib and dasatinib for treating patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The trial found that a daily asciminib dose of 80mg alongside dasatinib at 140mg proved well-tolerated, with encouraging measurable residual disease (MRD) responses. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Novartis, Pfizer, Jazz
Research Funding: Novartis, AbbVie
